AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23298553 — intervention group
Group type: COMPARATOR
Intervention: Non-co-enrolled patients in thromboprophylaxis trial
Number of subjects: 3746
Study 22000847 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole 150 mg single dose
Number of subjects: 142
Study 22000847 — intervention group
Group type: COMPARATOR
Intervention: Intra-vaginal clotrimazole 200 mg per day for six days
Number of subjects: 142
Study 18374245 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-traditional neighborhoods (experimental group)
Number of subjects: 32
Study 18374245 — intervention group
Group type: COMPARATOR
Intervention: Conventional suburban neighborhoods (control group)
Number of subjects: 32
Study 18374245 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors (e.g., fewer culs-de-sac)
Number of subjects: 32
Study 18374245 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-use mix
Number of subjects: 32
Study 16927177 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (DVPX)
Number of subjects: 71
Study 16927177 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 71
Study 12839615 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate foam (BVF)
Number of subjects: 61
Study 12839615 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate lotion (BDL)
Number of subjects: 61
Study 10607678 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy with autologous stem cell support (NMSG #5/94)
Number of subjects: 348
Study 10607678 — intervention group
Group type: COMPARATOR
Intervention: Control group (historic population)
Number of subjects: 348
Study 10607678 — intervention group
Group type: EXPERIMENTAL
Intervention: All registered patients in both populations
Number of subjects: 348
Study 9252721 — intervention group
Group type: EXPERIMENTAL
Intervention: FEMP+PSK (5-fluorouracil, cyclophosphamide, mitomycin C, predonisolone + 3.0 g of PSK)
Number of subjects: 134
Study 9252721 — intervention group
Group type: COMPARATOR
Intervention: FEMP (5-fluorouracil, cyclophosphamide, mitomycin C, predonisolone)
Number of subjects: 134
Study 9252721 — intervention group
Group type: COMPARATOR
Intervention: NA (no adjuvant therapy)
Number of subjects: 134
Study 1556679 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Meclofenamate (Meclomen) 100 mg po tid
Number of subjects: 0
Study 1556679 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac Sodium (Voltaren) 25 mg po tid
Number of subjects: 0
Study 1556679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Meclomen and Voltaren
Number of subjects: 0
Study 1556679 — intervention group
Group type: EXPERIMENTAL
Intervention: WOMAC Osteoarthritis Index
Number of subjects: 0
Study 3905199 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous digital subtraction angiography
Number of subjects: 28
Study 3905199 — intervention group
Group type: COMPARATOR
Intervention: Aortography
Number of subjects: 28
Study 30342554 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) therapy, 16 mg per day (8 mg twice daily, days 1 to 4), halved every 3 days until 0.5 mg on day 19, stopped on day 20.
Number of subjects: 420
Study 30342554 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) therapy
Number of subjects: 420
Study 30342554 — intervention group
Group type: COMPARATOR
Intervention: Burr-hole craniotomy (BHC)
Number of subjects: 420
Study 27232899 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide solution (H2O2) for 3 months
Number of subjects: 131
Study 27232899 — intervention group
Group type: COMPARATOR
Intervention: Biguanide‐preserved multipurpose solution (BMPS) for 3 months
Number of subjects: 131
Study 27232899 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide solution (H2O2)
Number of subjects: 131
Study 24405579 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group received access to a 'Rolling Store', nutrition education, and physical activity.
Number of subjects: 49
Study 24405579 — intervention group
Group type: COMPARATOR
Intervention: Control group received family coping classes.
Number of subjects: 49
Study 23239249 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider job aid intervention for managing late-returning clients
Number of subjects: 5000
Study 23239249 — intervention group
Group type: COMPARATOR
Intervention: Control group (no job aid)
Number of subjects: 5000
Study 20179024 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, immersive virtual pedestrian environment
Number of subjects: 240
Study 20179024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedestrian safety training via widely used video and computer strategies
Number of subjects: 240
Study 20179024 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised behavioural training at streetside locations
Number of subjects: 240
Study 20179024 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 240
Study 18757179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 9
Study 18757179 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 9
Study 16463811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative percent time below CPP thresholds (55 mm Hg)
Number of subjects: 157
Study 16463811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative percent time below CPP thresholds (60 mm Hg)
Number of subjects: 157
Study 16463811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative percent time below CPP thresholds (65 mm Hg)
Number of subjects: 157
Study 16463811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative percent time below CPP thresholds (70 mm Hg)
Number of subjects: 157
Study 16463811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative percent time below CPP thresholds
Number of subjects: 157
Study 12358368 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (5 mg/kg)
Number of subjects: 20
Study 12358368 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g)
Number of subjects: 20
Study 10748445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor consistency measurement in pathologically positive node group (PN[+]) in T1
Number of subjects: 53
Study 10748445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor consistency measurement in pathologically negative node group (PN[-]) in T1
Number of subjects: 53
Study 10748445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor consistency measurement in pathologically positive node group (PN[+]) in T2
Number of subjects: 53
Study 10748445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor consistency measurement in pathologically negative node group (PN[-]) in T2
Number of subjects: 53
Study 10748445 — intervention group
Group type: EXPERIMENTAL
Intervention: N0 patients with pathologically positive node group (PN[+])
Number of subjects: 53
Study 8809610 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon‐alpha 2b, 0.5 million per cm2 of keloid, injected into one lesional site
Number of subjects: 22
Study 8809610 — intervention group
Group type: COMPARATOR
Intervention: Diluent alone injected into another lesional site
Number of subjects: 22
Study 1301128 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic medications
Number of subjects: 1498
Study 1301128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1498
Study 3516257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetiedil at 0.4 mg/kg body weight
Number of subjects: 67
Study 3516257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 30952602 — intervention group
Group type: EXPERIMENTAL
Intervention: ECGs with a checklist of syncope-related etiologies
Number of subjects: 165
Study 30952602 — intervention group
Group type: COMPARATOR
Intervention: ECGs without a checklist
Number of subjects: 165
Study 30952602 — intervention group
Group type: EXPERIMENTAL
Intervention: ECGs with a checklist
Number of subjects: 165
Study 29432967 — intervention group
Group type: EXPERIMENTAL
Intervention: Timothy grass SLIT‐T taken once daily for 4 months
Number of subjects: 0
Study 29432967 — intervention group
Group type: COMPARATOR
Intervention: Placebo taken once daily for 4 months
Number of subjects: 0
Study 29432967 — intervention group
Group type: EXPERIMENTAL
Intervention: Timothy grass SLIT‐T
Number of subjects: 0
Study 29432967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29052340 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir (LPV) based ART
Number of subjects: 105
Study 29052340 — intervention group
Group type: COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitor (NNRTI) based ART
Number of subjects: 105
Study 25732273 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amount, low-intensity exercise (LALI)
Number of subjects: 300
Study 25732273 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amount, low-intensity exercise (HALI)
Number of subjects: 300
Study 25732273 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amount, high-intensity exercise (HAHI)
Number of subjects: 300
Study 25732273 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise groups
Number of subjects: 300
Study 25732273 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 300
Study 24050970 — intervention group
Group type: EXPERIMENTAL
Intervention: Eperisone hydrochloride (3 doses of 50 mg each)
Number of subjects: 24
Study 24050970 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac (2 doses of 100 mg each)
Number of subjects: 24
Study 24050970 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of eperisone hydrochloride and aceclofenac
Number of subjects: 24
Study 24050970 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 20091161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 100-400 mg
Number of subjects: 38
Study 20091161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 18241749 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 345
Study 18241749 — intervention group
Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 345
Study 16874563 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching-to-sample procedure with varying retention intervals
Number of subjects: 0
Study 16874563 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching-to-sample procedure
Number of subjects: 0
Study 12802748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (1 g daily for 7 days; n=87)
Number of subjects: 173
Study 12802748 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sodium penicillin G (1.5 million U every 6 h for 7 days; n=86)
Number of subjects: 173
Study 12802748 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 173
Study 12802748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 173
Study 12802748 — intervention group
Group type: COMPARATOR
Intervention: Sodium penicillin G
Number of subjects: 173
Study 10566924 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg oral clonidine
Number of subjects: 0
Study 10566924 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg oral clonidine
Number of subjects: 0
Study 10566924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8619356 — intervention group
Group type: EXPERIMENTAL
Intervention: iobitridol 300
Number of subjects: 180
Study 8619356 — intervention group
Group type: COMPARATOR
Intervention: iohexol 300
Number of subjects: 180
Study 1819317 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol sodium (prostacyclin)
Number of subjects: 30
Study 1819317 — intervention group
Group type: COMPARATOR
Intervention: Heparin sodium
Number of subjects: 30
Study 6215056 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid
Number of subjects: 48
Study 31269004 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT)
Number of subjects: 38
Study 31269004 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Training (MIT)
Number of subjects: 38
Study 28991146 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediational Intervention for Sensitizing Caregivers (MISC) training emphasizing cognitive stimulation
Number of subjects: 221
Study 28991146 — intervention group
Group type: COMPARATOR
Intervention: UCOBAC program that delivered health and nutrition training
Number of subjects: 221
Study 25896457 — intervention group
Group type: EXPERIMENTAL
Intervention: KAMRA small-aperture inlay
Number of subjects: 507
Study 25896457 — intervention group
Group type: COMPARATOR
Intervention: Crystalens Advanced Optics (AO)
Number of subjects: 507
Study 25896457 — intervention group
Group type: COMPARATOR
Intervention: AcrySof IQ ReSTOR +3.0 D
Number of subjects: 507
Study 25896457 — intervention group
Group type: COMPARATOR
Intervention: Tecnis +4D Multifocal (MF)
Number of subjects: 507
Study 23710812 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-CGM group
Number of subjects: 123
Study 23710812 — intervention group
Group type: COMPARATOR
Intervention: GM group (control)
Number of subjects: 123
Study 21248199 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein and high PRAL diet (HPHP; total protein: 118 g/d; PRAL: 33 mEq/d)
Number of subjects: 16
Study 21248199 — intervention group
Group type: COMPARATOR
Intervention: Low protein and low PRAL diet (LPLP; total protein: 61 g/d; PRAL: ‐48 mEq/d)
Number of subjects: 16
Study 19549294 — intervention group
Group type: COMPARATOR
Intervention: Physical Training (PT)
Number of subjects: 254
Study 19549294 — intervention group
Group type: COMPARATOR
Intervention: Physical Training with Cognitive Behavioral Component and Workplace Specific Exercises (PTCBWE)
Number of subjects: 254
Study 19549294 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care (corresponding to PT)
Number of subjects: 254
Study 19549294 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care (corresponding to PTCBWE)
Number of subjects: 254
Study 18177195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft lip participants
Number of subjects: 84
Study 18177195 — intervention group
Group type: COMPARATOR
Intervention: Noncleft participants
Number of subjects: 84
Study 15049467 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11499461 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Presentation Management (PPM) and Negative Presentation Management (NPM) validity scales
Number of subjects: 369
Study 11499461 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM - PPM index
Number of subjects: 369
Study 9745413 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg.week recombinant human GH
Number of subjects: 62
Study 8751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 1.5 mg
Number of subjects: 248
Study 8751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg
Number of subjects: 248
Study 8751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg
Number of subjects: 248
Study 8751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5/10 mg
Number of subjects: 248
Study 8751029 — intervention group
Group type: COMPARATOR
Intervention: Pooled Spirapril groups
Number of subjects: 248
Study 8751029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 2533374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortison and local anaesthetic injected intra‐articularly into two facet joints (28 patients)
Number of subjects: 109
Study 2533374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortison and local anaesthetic injected pericapsularly around two facet joints (39 patients)
Number of subjects: 109
Study 2533374 — intervention group
Group type: COMPARATOR
Intervention: Physiologic sodium hydrochloride injected intra‐articularly into two facet joints (42 patients)
Number of subjects: 109
Study 83697 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-visual teaching aids
Number of subjects: 0
Study 83697 — intervention group
Group type: COMPARATOR
Intervention: Printed teaching aids
Number of subjects: 0
Study 29948216 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polyphenols cocoa powder
Number of subjects: 20
Study 29948216 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrins (control)
Number of subjects: 20
Study 27925426 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powder (MNP) for 2-3 months
Number of subjects: 794
Study 27925426 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 794
Study 26464495 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma injection
Number of subjects: 54
Study 26464495 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline injection
Number of subjects: 54
Study 26464495 — intervention group
Group type: COMPARATOR
Intervention: N/A (baseline echo types I + II)
Number of subjects: 54
Study 25095774 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication at 0.06% and 0.10% blood alcohol concentration
Number of subjects: 25
Study 23138238 — intervention group
Group type: EXPERIMENTAL
Intervention: Periacetabular osteotomy with femoral head-neck osteochondroplasty
Number of subjects: 88
Study 23138238 — intervention group
Group type: COMPARATOR
Intervention: Isolated periacetabular osteotomy
Number of subjects: 88
Study 19665770 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk oral immunotherapy (MOIT)
Number of subjects: 0
Study 17886454 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin coating consisting of a self-etching primer bonding system (Clearfil SE Bond) and a low-viscosity microfilled resin (Protect Liner F) applied to 10 cavities.
Number of subjects: 20
Study 17886454 — intervention group
Group type: COMPARATOR
Intervention: No resin coating applied (non-coating group) in the other 10 cavities.
Number of subjects: 20
Study 15064544 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency coagulation
Number of subjects: 80
Study 15064544 — intervention group
Group type: COMPARATOR
Intervention: Rubber band ligation
Number of subjects: 80
Study 12053028 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of oral sildenafil citrate combined with self‐manual and visual sexual stimulation
Number of subjects: 41
Study 12053028 — intervention group
Group type: COMPARATOR
Intervention: Combined intracavernosal injection of 60 mg of papaverine and sexual stimulation (CIS)
Number of subjects: 41
Study 10444027 — intervention group
Group type: EXPERIMENTAL
Intervention: SC602 vaccine
Number of subjects: 36
Study 7916183 — intervention group
Group type: EXPERIMENTAL
Intervention: RP 56976 (docetaxel) at 60 mg/m2
Number of subjects: 27
Study 7916183 — intervention group
Group type: EXPERIMENTAL
Intervention: RP 56976 (docetaxel) at 70-90 mg/m2
Number of subjects: 27
Study 7916183 — intervention group
Group type: EXPERIMENTAL
Intervention: RP 56976 (docetaxel)
Number of subjects: 27
Study 2666293 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (1 40 mg tablet at night)
Number of subjects: 143
Study 2666293 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (2 150 mg tablets at night)
Number of subjects: 143
Study 1234507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular salbutamol (8 mug/kg)
Number of subjects: 6
Study 1234507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular salbutamol (4 mug/kg)
Number of subjects: 6
Study 1234507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular salbutamol (12 mug/kg)
Number of subjects: 6
Study 1234507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30712734 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week expressive writing intervention (Transform Your Life: Write to Heal)
Number of subjects: 39
Study 28343658 — intervention group
Group type: EXPERIMENTAL
Intervention: TEACH text message intervention (45 unique text messages over 3 months)
Number of subjects: 61
Study 28343658 — intervention group
Group type: COMPARATOR
Intervention: Standard of care treatment (control group)
Number of subjects: 61
Study 24986051 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraBite jaw exercise device
Number of subjects: 50
Study 24986051 — intervention group
Group type: COMPARATOR
Intervention: Engström jaw exercise device
Number of subjects: 50
Study 23800615 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants not told the speaker had schizophrenia
Number of subjects: 0
Study 23800615 — intervention group
Group type: COMPARATOR
Intervention: Participants told the speaker had schizophrenia
Number of subjects: 0
Study 21659887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Number of subjects: 17
Study 21659887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 17869079 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2g IV Magnesium sulphate
Number of subjects: 129
Study 17869079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 17054107 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (Lan ATG) 120 mg every 6 weeks
Number of subjects: 60
Study 17054107 — intervention group
Group type: COMPARATOR
Intervention: Lanreotide microparticles (Lan MP) 60 mg every 3 weeks
Number of subjects: 60
Study 17054107 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study 15333422 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding supplemented with antioxidants (vitamins C and E)
Number of subjects: 216
Study 15333422 — intervention group
Group type: COMPARATOR
Intervention: Control group (isocaloric formula)
Number of subjects: 216
Study 11550163 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (RT+) with 25 grays in 1 week
Number of subjects: 557
Study 11550163 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (RT-)
Number of subjects: 557
Study 11550163 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (RT+)
Number of subjects: 557
Study 11550163 — intervention group
Group type: EXPERIMENTAL
Intervention: All included patients with preoperative radiotherapy (RT+)
Number of subjects: 557
Study 9024246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9024246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (8 mg)
Number of subjects: 6
Study 9024246 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (1 g)
Number of subjects: 6